Dermatomyositis clinical trials at UCLA

2 in progress, 1 open to eligible people

Showing trials for

  • Brepocitinib in Adults With Dermatomyositis

    open to eligible people ages 18-75

    This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib.

    Los Angeles, California and other locations

  • IgPro20 in Adults With Dermatomyositis (DM)

    Sorry, in progress, not accepting new patients

    This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder status based on Total Improvement Score (TIS) assessments.

    Los Angeles, California and other locations

Last updated: